Alpha-Lipoic Acid: R-ALA, Amounts, and Label Guide

Alpha-Lipoic Acid is made in the body and functions as a cofactor for mitochondrial enzyme complexes involved in energy metabolism. Its oxidized and reduced forms also participate in redox chemistry, which is why supplement labels often place it under an antioxidant or mitochondrial-support headline. ¹

Those biochemical roles explain why ALA is biologically relevant. They do not show that a capsule will improve energy, reverse nerve damage, control glucose, remove toxins, slow aging, or cause meaningful weight loss. Each consumer claim still needs human evidence that matches the preparation, dose, route, population, duration, and measured outcome.

ALA can mean two different ingredients

In this guide, ALA means Alpha-Lipoic Acid. The same abbreviation is also used for alpha-linolenic acid, an omega-3 fatty acid found in flaxseed oil and other foods. A bare “ALA” line without the full name or clear formula context is therefore ambiguous. Do not infer the identity from the abbreviation alone.

Standard Alpha-Lipoic Acid supplements commonly contain a racemic mixture of R- and S-enantiomers. R-lipoic acid is the naturally occurring enantiomer and is also sold on its own. Sodium R-lipoate is a sodium salt of R-lipoic acid used in some stabilized materials. Small pharmacokinetic studies show that formulation can change absorption, but they do not establish one universal form as clinically superior for every consumer claim. ^{1, 8}

The label must also clarify what its milligram number refers to. A sodium R-lipoate material weight and a separately stated “providing X mg R-lipoic acid” value are not the same quantity. Use the explicitly declared active amount when the manufacturer provides one; do not apply a generic conversion to every branded or stabilized material.

Alpha-Lipoic Acid does not have an established U.S. Daily Value, so a U.S. Supplement Facts panel usually cannot give it a meaningful percent Daily Value. The practical comparison is the stated amount per listed serving, the serving size, the exact form wording, and whether the individual amount is visible. ⁹

Keep the amount attached to the exact ALA form

Start with the full serving and require enough wording to distinguish Alpha-Lipoic Acid from alpha-linolenic acid when the abbreviation ALA appears. Then keep standard ALA, R-ALA, sodium R-lipoate material, and any separately declared active equivalent as distinct label quantities.

A clearly disclosed amount can be compared across products. An unknown share of a proprietary blend cannot. For the broader method, see How to Read Supplement Labels.

A standalone ALA capsule can overlap with a glucose formula, a nerve-health product, or a broad antioxidant blend. Other ingredients such as chromium, berberine, thiamine derivatives, or Acetyl-L-Carnitine can change the formula context without changing the disclosed ALA amount.

When products are added to My Stack, NutriDetector can compare supported Alpha-Lipoic Acid wording, disclosed amounts per listed serving, serving context, and co-ingredients across saved supplements. A clearly stated amount and an unknown share of a proprietary blend remain different kinds of label information.

Amounts of 300 mg and 600 mg are common on ALA labels, and 600 mg daily appears frequently in neuropathy research. Studies have also used other amounts, intravenous administration, and medically defined populations. An intravenous study dose is not interchangeable with an over-the-counter oral serving, and a commonly studied amount is not a personal recommendation. ^{2, 3}

A 2020 meta-analysis of 71 randomized placebo-controlled studies did not find a significant increase in overall treatment-emergent adverse events with ALA. That pooled result is reassuring for the studied settings, but it does not remove uncertainty about rare reactions, long-term use, large accidental ingestions, or an individual’s medicine and health context. Gastrointestinal symptoms are among the more commonly reported tolerability issues. ⁷

A rare hypoglycemia signal has no established threshold

EFSA reviewed reports linking supplemental ALA with insulin autoimmune syndrome, a rare condition that can cause hypoglycemia in genetically susceptible people. EFSA concluded that ALA added to foods and supplements is likely to increase that risk in susceptible individuals and could not determine a dose below which the syndrome would not be expected to occur. This is a rare risk, not evidence that ordinary ALA use commonly causes the condition. ⁶

ALA is often combined with ingredients marketed for glucose support. Human trials have measured glucose-related outcomes, even though the average changes in the 2022 meta-analysis were not judged clinically important. A person using glucose-lowering medicine or experiencing possible hypoglycemia still needs the whole regimen reviewed rather than assuming a supplement is irrelevant because the average trial effect was small. ^{4, 6}

Pregnancy, breastfeeding, childhood use, regular medicines, and treatment for diabetes or neurological symptoms require more context than a Supplement Facts panel provides. New or unexplained sweating, trembling, confusion, faintness, or other possible hypoglycemia symptoms warrant prompt clinical assessment rather than a label-only interpretation.